Oncology · 2005
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of adjuvant tamoxifen
Tamoxifen had been in clinical use for early breast cancer since the 1970s, and several randomized trials had confirmed that it reduced recurrence. What those individual trials could not do was quantify the long-term survival benefit with precision, particularly beyond five years, or reliably identify which subgroups gained and which did not. The Early Breast Cancer Trialists' Collaborative Group, founded at Oxford with Richard Peto as its statistical architect, existed specifically to answer questions of that kind by pooling raw patient-level data from every eligible trial rather than working from published summaries.
The 2005 Lancet meta-analysis assembled individual patient data from roughly 20 randomized trials of adjuvant tamoxifen in early breast cancer, covering tens of thousands of women followed for up to 15 years. In patients with estrogen receptor-positive tumors, five years of tamoxifen reduced the annual breast cancer death rate by 31% (standard error 3%). That proportionate reduction was consistent across age groups and nodal status categories, though the absolute gain varied with baseline risk.
Among the most clinically significant results was the finding that the survival benefit continued accumulating to at least 15 years after diagnosis, well beyond the five-year treatment period. Earlier analyses had documented short-term gain; the 2005 data showed the mortality reduction was not merely a delay in events but a genuine long-term protection. In ER-negative tumors, tamoxifen offered no meaningful benefit, a result that reinforced receptor testing as a prerequisite before prescribing adjuvant endocrine therapy.
Mitch Dowsett at the Royal Marsden contributed to understanding the biological basis for tamoxifen's effects, including its partial agonist activity and the relevance of ER expression levels. Those biological refinements helped explain why some ER-positive patients responded better than others and informed the development of aromatase inhibitors as an alternative and subsequently a preferred agent in postmenopausal women.
The methodology EBCTCG used in 2005, collecting and harmonizing raw trial data from dozens of research groups worldwide, became the framework for subsequent overviews on polychemotherapy, aromatase inhibitors, and radiotherapy. Decision-support tools used in oncology clinics to estimate absolute benefit from adjuvant treatment incorporated the EBCTCG's quantification of tamoxifen's effect by age, nodal status, and ER level. Those tools remain in routine use.
Key People
- Richard Peto — Oxford; co-founder, EBCTCG; statistical methodology
- Mitch Dowsett — Royal Marsden; ER biology and tamoxifen pharmacology contributor
Lancet, 2005